SCHEMBL6778346

SCHEMBL6778346

O=C1c2ccccc2C(=O)N1CCCCCCCC(O)CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HDAC1 Q13547 5/20 0.52
HDAC7 Q8WUI4 5/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC3 O15379 2/20 0.52
HDAC4 P56524 2/20 0.52
HDAC2 Q92769 2/20 0.52
HDAC10 Q969S8 2/20 0.52
HDAC11 Q96DB2 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC9 Q9UKV0 2/20 0.52
HDAC5 Q9UQL6 2/20 0.52
ALDH1A1 P00352 1/20 0.51
MAOB P27338 2/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.49
CYP1A2 P05177 1/20 0.49
CHRM2 P08172 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779279 1.00 TDP1 (0.54) TDP1L3MBTL1HDAC1HDAC7HDAC8
SCHEMBL20707259 0.98 HDAC1 (0.53) TDP1L3MBTL1HDAC1HDAC7HDAC8
SCHEMBL6774135 0.98 HDAC1 (0.53) TDP1L3MBTL1HDAC1HDAC7HDAC8
SCHEMBL751414 0.94 ALDH1A1 (0.54) TDP1L3MBTL1HDAC1HDAC7HDAC8
SCHEMBL368756 0.87 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2
SCHEMBL10673491 0.84 TDP1 (0.54) TDP1L3MBTL1HDAC1HDAC7HDAC8
SCHEMBL16392601 0.84 ACHE (0.60) MAOBACHE
SCHEMBL8019454 0.84 KMT2A (0.53) HDAC1HDAC7HDAC8HDAC3HDAC4
SCHEMBL8070917 0.83 CHRM2 (0.58) TDP1L3MBTL1MAOBMEN1CYP1A2
SCHEMBL2604742 0.81 TDP1 (0.75) TDP1L3MBTL1HDAC1HDAC7HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693105-B1 USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL CELL THERAPEUTICS, INC. 2004-02-17 US disclosed
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US disclosed
EP-0669825-A4 HYDROXYL-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-03 EP disclosed
EP-0669825-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-09-06 EP disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed